All In Biotech

Drug Trial Radar · NCT01476787

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,030 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,030

Actual

Start

Dec 29, 2011

Primary completion

Apr 30, 2024

Study completion Apr 30, 2024

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
The Lymphoma Academic Research Organisation
First posted
Nov 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.

Conditions

  • Follicular Lymphoma

Interventions

  • RituximabDrug

    375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

  • LenalidomideDrug

    20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles

  • Rituximab-CHOPDrug

    7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

  • Rituximab-CVPDrug

    7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

  • Rituximab-BendamustineDrug

    7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central ReviewTime frame: At 120 weeks
  2. Progression-free Survival (PFS)Time frame: From randomization into the study to the first observation of documented disease progression or death due to any cause (up to approximately 140 months).

Locations

36 sites in 2 countries. Site status is shown where the registry gives one.

  • Local Institution - 54103

    Chandler, Arizona

  • Local Institution - 51803

    Fullerton, California

  • Local Institution - 52003

    Los Angeles, California

  • Local Institution - 51603

    Colorado Springs, Colorado

  • Local Institution - 52503

    Englewood, Florida

  • Local Institution - 51703

    Orlando, Florida

  • Local Institution - 53803

    St. Petersburg, Florida

  • Local Institution - 50803

    Chicago, Illinois

  • Local Institution - 52203

    Lexington, Kentucky

  • Local Institution - 53603

    Westminster, Maryland

  • Local Institution - 50403

    Boston, Massachusetts

  • Local Institution - 50503

    Boston, Massachusetts

  • Local Institution - 53003

    Southfield, Michigan

  • Local Institution - 51003

    St Louis, Missouri

  • Local Institution - 54403

    Cherry Hill, New Jersey

  • Local Institution - 53703

    Hackensack, New Jersey

  • Local Institution - 50903

    Morristown, New Jersey

  • Local Institution - 54303

    Sparta, New Jersey

  • Local Institution - 52403

    New York, New York

  • Local Institution - 50203

    New York, New York

  • Local Institution - 51303

    Nashville, Tennessee

  • Local Institution - 51203

    Dallas, Texas

  • Local Institution - 51103

    Houston, Texas

  • Local Institution - 54003

    Lubbock, Texas

  • Local Institution - 53303

    Richmond, Virginia

  • Local Institution - 52703

    Seattle, Washington

  • Local Institution - 40922

    Fukuoka, Japan

  • Local Institution - 40422

    Hiroshima, Japan

  • Local Institution - 40122

    Isehara City, Kanagawa, Japan

  • Local Institution - 40322

    Kobe, Japan

  • Local Institution - 40622

    Kyoto, Japan

  • Local Institution - 41022

    Sendai, Japan

  • Local Institution - 40522

    Shizuoka, Japan

  • Local Institution - 40722

    Chuo-ku, Tokyo, Japan

  • Local Institution - 40222

    Koto-ku, Tokyo, Japan

  • Local Institution - 41122

    Minato-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.